Taro Pharmaceutical Industries (TARO) USPTO patents

Utility

Compositions Comprising Desoximetasone and Tazarotene

23 Feb 23

The present disclosure provides formulations comprising desoximetasone, tazarotene, a polymer comprising polyurethane, and a solvent.

Xiaopin JIN, Bean NEZIR, Brenden HADJIKEZIAN, Shen GAO, Ron SCHLINGER, Avi AVRAMOFF

Filed: 30 Dec 20

Utility

Stable Topical Compositions of Fenoldopam

23 Feb 23

The present disclosure is directed to a topical composition, e.g., a physically and chemically stable topical composition of Fenoldopam comprising about 0.1% to about 5% by weight of Fenoldopam or a pharmaceutically acceptable salt thereof, at least one polyacrylamide-type gelling agent, at least one cellulose-type gelling agent, and at least one solvent, wherein the Fenoldopam is substantially solubilized in the composition, and wherein the composition is stable for at least twelve months at 25° C. and 60% relative humidity.

Helena SHIFRIN, Alexandra SHRAIFEL, Vered ROSENBERGER, Ron SCHLINGER, Tzviel SHESKIN, Avi AVRAMOFF

Filed: 9 Aug 22

Utility

Preparation of Trifarotene and Intermediates and Polymorphs Thereof

16 Feb 23

Ilana OZER, Yulia KAFTANOV, Elliot SIMHON, Andrey DUSHKIN, Shani SHEFFER DEE-NOOR, Hillel PIZEM, Avi AVRAMOFF

Filed: 10 Dec 20

Utility

Topical capecitabine for the treatment of hyperproliferative skin conditions

24 Jan 23

The present invention relates to a novel and unexpected method of using topical Capecitabine composition to obtain therapeutically effective amounts of fluorouracil (FU) within the skin of a subject afflicted with hyperproliferative or inflammatory skin condition.

Avi Avramoff, Helena Shifrin, Ron Schlinger, Tzviel Sheskin, Zeev Elkoshi

Filed: 18 Jan 19

Utility

Stable topical compositions of fenoldopam

20 Sep 22

The present disclosure is directed to a topical composition, e.g., a physically and chemically stable topical composition of Fenoldopam comprising about 0.1% to about 5% by weight of Fenoldopam or a pharmaceutically acceptable salt thereof, at least one polyacrylamide-type gelling agent, at least one cellulose-type gelling agent, and at least one solvent, wherein the Fenoldopam is substantially solubilized in the composition, and wherein the composition is stable for at least twelve months at 25° C. and 60% relative humidity.

Helena Shifrin, Alexandra Shraifel, Vered Rosenberger, Ron Schlinger, Tzviel Sheskin, Avi Avramoff

Filed: 6 Mar 20

Utility

Stable Topical Compositions of Fenoldopam

10 Feb 22

The present disclosure is directed to a topical composition, e.g., a physically and chemically stable topical composition of Fenoldopam comprising about 0.1% to about 5% by weight of Fenoldopam or a pharmaceutically acceptable salt thereof, at least one polyacrylamide-type gelling agent, at least one cellulose-type gelling agent, and at least one solvent, wherein the Fenoldopam is substantially solubilized in the composition, and wherein the composition is stable for at least twelve months at 25° C. and 60% relative humidity.

Helena SHIFRIN, Alexandra SHRAIFEL, Vered ROSENBERGER, Ron SCHLINGER, Tzviel SHESKIN, Avi AVRAMOFF

Filed: 6 Mar 20

Utility

Topical Montelukast Formulations

20 Jan 22

The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.

Vered ROSENBERGER, Helena SHIFRIN, Irena OLEINIK, Tzviel SHESKIN, Ron SCHLINGER, Avi AVRAMOFF

Filed: 29 Sep 21

Utility

Topical Montelukast Formulations

23 Dec 21

The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.

Vered ROSENBERGER, Helena SHIFRIN, Irena OLEINIK, Tzviel SHESKIN, Ron SCHLINGER, Avi AVRAMOFF

Filed: 2 Aug 21

Utility

Topical Montelukast formulations

16 Nov 21

The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 μm, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.

Vered Rosenberger, Helena Shifrin, Irena Oleinik, Tzviel Sheskin, Ron Schlinger, Avi Avramoff

Filed: 2 Feb 21

Utility

Topical Montelukast Formulations

5 Aug 21

The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 μm, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.

Vered ROSENBERGER, Helena SHIFRIN, Irena OLEINIK, Tzviel SHESKIN, Ron SCHLINGER, Avi AVRAMOFF

Filed: 2 Feb 21

Utility

Topical Capecitabine for the Treatment of Hyperproliferative Skin Conditions

25 Feb 21

The present invention relates to a novel and unexpected method of using topical Capecitabine composition to obtain therapeutically effective amounts of fluorouracil (FU) within the skin of a subject afflicted with hyperproliferative or inflammatory skin condition.

Avi AVRAMOFF, Helena SHIFRIN, Ron SCHLINGER, Tzviel SHESKIN, Zeev ELKOSHI

Filed: 18 Jan 19

Utility

Topical Montelukast for Treatment of Atopic Dermatitis

29 Jul 20

A topical formulation comprising Montelukast or a pharmaceutically acceptable salt thereof, a gelling agent and water for the treatment of atopic dermatitis.

Avi AVRAMOFF, Helena SHIFRIN, Irena OLEINIK, Ron SCHLINGER, Tzviel SHESKIN, Vered ROSENBERGER

Filed: 8 Jan 20

Utility

Topical montelukast for treatment of atopic dermatitis

3 Feb 20

A topical formulation comprising Montelukast or a pharmaceutically acceptable salt thereof, a gelling agent and water for the treatment of atopic dermatitis.

Avi Avramoff, Helena Shifrin, Irena Oleinik, Ron Schlinger, Tzviel Sheskin, Vered Rosenberger

Filed: 2 May 17

Utility

Fenoldopam Topical Formulations for Treating Skin Disorders

30 Oct 19

Wahid KHAN, Helena SHIFRIN, Ron SCHLINGER, Avi AVRAMOFF, Avi DOMB

Filed: 29 Aug 17